AstraZeneca PLC - American Depositary Shares (NQ:AZN)

92.77 UNCHANGED

Last Price Updated: 4:00 PM EST, Jan 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about AstraZeneca PLC - American Depositary Shares

< Previous 1 2

...

26 27 28 29 30 31 32 33 34

...

75 76 Next >

AstraZeneca Strikes Deal With Absci To Leverage AI In Cancer Drug Discovery: Report ↗

December 04, 2023

AstraZeneca plc (NASDAQ: AZN) has reportedly finalized a partnership deal valued at up to $247 million with Absci Corporation (NASDAQ: ABSI), a U.S.-based firm specializing in artificial intelligence...

Via Benzinga

Topics Artificial Intelligence

Week In Review: Tang Capital Offers $465 Million For LianBio Plus 80% Of Any Licenses/Divestments ↗

December 02, 2023

LianBio received a $465 million buyout offer from Tang Capital Management. In addition, Tang also offered shareholders a contingent value right for 80% of net proceeds from any license or divestment of...

Via Talk Markets

Weight Loss Drugs And Associated Suicidal Thoughts - European Drug Regulator Seeks Clarifications From Drug Makers ↗

December 01, 2023

European Medicines Agency (EMA) will request further clarifications from drugmakers of GLP-1 receptor agonists for diabetes and weight loss, including Novo Nordisk A/S's (NYSE: NVO) popular therapies...

Via Benzinga

AstraZeneca Stops Two Lokelma Late-Stage Trials After Evaluating Potential Benefits ↗

December 01, 2023

AstraZeneca Plc (NASDAQ: AZN) discontinued the STABILIZE-

Via Benzinga

AstraZeneca advances scientific leadership in hematology at ASH 2023

November 29, 2023

From AstraZeneca

Via Business Wire

Industry Comparison: Evaluating AstraZeneca Against Competitors In Pharmaceuticals Industry ↗

November 27, 2023

Via Benzinga

Investigating AstraZeneca's Standing In Pharmaceuticals Industry Compared To Competitors ↗

November 13, 2023

Via Benzinga

Week In Review: BeiGene Signs $1.3 Billion Deal For Preclinical CDK2 Inhibitor From Boston’s Ensem ↗

November 25, 2023

Beijing’s BeiGene acquired global rights to a preclinical novel cyclin-dependent kinase 2 (CDK2) inhibitor from Boston’s Ensem Therapeutics in a $1.3 billion agreement. Ensem will receive an upfront...

Via Talk Markets

Eli Lilly and Novo Nordisk Are Big Names in Weight Loss, but Investors Shouldn't Count Out This Healthcare Giant ↗

November 22, 2023

Could AstraZeneca be an under-rated buy right now?

Via The Motley Fool

3 No-Brainer Stocks to Buy With $1,000 Right Now ↗

November 22, 2023

A modest amount of money can go a long way when it's invested in industry-leading businesses with sustained, long-term catalysts.

Via The Motley Fool

5 Growth Stocks to Buy for 2024 ↗

November 20, 2023

Forget the "Magnificent 7." These are the top five growth stocks to buy in the coming year for interested investors.

Via InvestorPlace

AstraZeneca launches Evinova, a health-tech business to accelerate innovation across the life sciences sector, the delivery of clinical trials and better health outcomes

November 20, 2023

From AstraZeneca

Via Business Wire

3 stocks that crushed earnings estimates and still tanked

November 20, 2023

Every earnings season, regardless of sector or industry, has its share of stocks that go down even after beating earnings expectations such as these stocks

Via MarketBeat

US CDC Rolls Out Additional Doses For Sanofi/AstraZeneca Recently Approved Respiratory Infection Drug As Demand Surges ↗

November 17, 2023

The U.S.

Via Benzinga

AstraZeneca Is Trying to Make an Ozempic Competitor (Again), but Don't Rush to Buy the Stock ↗

November 17, 2023

It might have a hard time finding a home in the market.

Via The Motley Fool

FDA Approves AstraZeneca's Truqap/Faslodex Combo Therapy For Breast Cancer, Competes With Gilead's Drug ↗

November 17, 2023

FDA approves AstraZeneca Plc's (NASDAQ: AZN) Truqap (capivasertib) in combination with Faslodex (fulvestrant) for the treatment of adult patients with hormone receptor (HR)-positive, HER2-negative...

Via Benzinga

TRUQAP™ (capivasertib) plus fulvestrant approved in the US for patients with advanced HR-positive breast cancer

November 17, 2023

From AstraZeneca

Via Business Wire

FDA Approves Bristol-Myers' Lung Cancer Drug Acquired Via $4B Turning Point Deal: Competes With Roche, Merck, AstraZeneca ↗

November 16, 2023

The FDA approved Bristol Myers Squibb And Co's (NYSE: BMY) Augtyro (repotrectinib) for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small

Via Benzinga

AstraZeneca's Flagship Cancer Drug Imfinzi Fails On Main Goal In Lung Cancer Trial When Combined With Chemoradiotherapy ↗

November 14, 2023

AstraZeneca Plc (NASDAQ: AZN) said its PACIFIC

Via Benzinga

Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyes $200 Billion GLP-1 Market with its DehydraTECH(TM) Technology

November 14, 2023

Via CannabisNewsWire

Topics Intellectual Property

Royal Rule: Buy These 3 Dividend Aristocrats on Every. Single. Dip. ↗

November 13, 2023

Choosing dividend aristocrats to buy becomes easy when you elect to buy the royalty of income-generating stocks.

Via InvestorPlace

Week In Review: Eccogen Out-Licenses GLP-1 Agonist To AstraZeneca In $2 Billion Deal ↗

November 11, 2023

Eccogene, a Shanghai-Boston biotech, out-licensed global rights (ex-China) for its novel small molecule GLP-1 agonist to AstraZeneca in a $2 billion blockbuster deal. Eccogene will receive $185 million...

Via Talk Markets

The 7 Next Trillion Dollar Companies to Invest in to Become a Millionaire ↗

November 10, 2023

These are the next trillion-dollar companies to buy as they represent strong business fundamentals with robust cash flow upside potential.

Via InvestorPlace

AstraZeneca Plc (AZN) Q3 2023 Earnings Call Transcript ↗

November 09, 2023

AZN earnings call for the period ending September 30, 2023.

Via The Motley Fool

Topics Earnings

Auto Trader & AstraZeneca Help FTSE Reverse Early Losses ↗

November 09, 2023

As the day progressed, the initial downturn was reversed, and the blue-chip index managed to secure gains just shy of 1%.

Via Talk Markets

AstraZeneca Is Making A $2 Billion Bet To Rival Lilly, Novo In Obesity Drugs ↗

November 09, 2023

The company is licensing a new GLP-1 drug in the hopes of taking on Novo and Lilly.

Via Investor's Business Daily

AstraZeneca Joins Anti-Obesity Race Dominated By Eli Lilly And Novo Nordisk, Reports Mixed Q3 Earnings ↗

November 09, 2023

AstraZeneca Plc (NASDAQ: AZN) has reported Q3 FY23 core EPS of $1.73, u

Via Benzinga

Wall Street To Snap Longest Winning Streak Since 2021 Today? Earnings, Bond Yields In Focus Ahead Of Powell's Speech ↗

November 09, 2023

The stock market’s momentum appears to be waning, and futures suggest a mixed opening for Thursday. Earnings reports have generally been positive, with companies like Walt Disney Co.

Via Benzinga

Earnings Review: AstraZeneca Increases Profit Outlook, Reports 17% EPS Growth ↗

November 09, 2023

AstraZeneca reported an EPS of $1.73 for Q3 2023 and $5.8 for 9M 2023.

Via Talk Markets

IMFINZI® (durvalumab) plus bevacizumab met primary endpoint for progression-free survival in liver cancer eligible for embolization in EMERALD-1 Phase III trial

November 09, 2023

From AstraZeneca

Via Business Wire

< Previous 1 2

...

26 27 28 29 30 31 32 33 34

...

75 76 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.